Literature DB >> 19923807

Intratympanic steroids for inner ear disorders: a review.

Amanda Hu1, Lorne S Parnes.   

Abstract

BACKGROUND/AIM: The use of intratympanic steroids (ITS) has proliferated over the past 10-15 years to include treatments for inner ear disorders, like Ménière's Disease (MD) and sudden sensorineural hearing loss (SSNHL). The aim of this study was to review the clinical trials of ITS for inner ear disorders.
METHODS: PubMed and Ovid Medline databases were searched from 1966 to present for clinical trials on ITS in the treatment of MD and SSNHL. Studies were evaluated based on comparability and internal and external validity.
RESULTS: Thirty-eight studies were identified in total, 13 studies on MD and 25 studies on SSNHL. Most studies lacked placebo controls. Only 3 studies were double-blinded randomized prospective trials. Overall, there were heterogeneous steroid doses, treatment protocols, previous treatments, and definitions of disease and improvement.
CONCLUSION: There are no good studies on ITS that meet the criteria of comparability, internal validity, and external validity. It is difficult to compare studies due to the heterogeneous nature of the data. More rigorously designed studies are required to determine the efficacy of this treatment, the optimal steroid to use, and the best treatment regimen. (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19923807     DOI: 10.1159/000241894

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  17 in total

1.  Intratympanic steroids in severe to profound sudden sensorineural hearing loss as salvage treatment.

Authors:  Jong Dae Lee; Moo Kyun Park; Chi-Kyou Lee; Kye Hoon Park; Byung Don Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-09-17       Impact factor: 3.372

2.  [Intratympanic glucocorticoid therapy of sudden hearing loss].

Authors:  S K Plontke
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

Review 3.  Menière's disease.

Authors:  Tony Wright
Journal:  BMJ Clin Evid       Date:  2015-11-05

4.  Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation.

Authors:  Alec N Salt; Jared Hartsock; Stefan Plontke; Carl LeBel; Fabrice Piu
Journal:  Audiol Neurootol       Date:  2010-12-19       Impact factor: 1.854

5.  Intratympanic dexamethasone injections for refractory Meniere' s disease.

Authors:  Hongmiao Ren; Tuanfang Yin; Yongde Lu; Weijia Kong; Jihao Ren
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  [Intratympanic steroid administration: use in the treatment of profound idiopathic sudden sensorineural hearing loss].

Authors:  C Burkart; T Linder; M Gärtner
Journal:  HNO       Date:  2013-02       Impact factor: 1.284

7.  Intratympanic Therapies for Menière's disease.

Authors:  Matthew W Miller; Yuri Agrawal
Journal:  Curr Otorhinolaryngol Rep       Date:  2014-09-01

8.  Long Term Outcomes of Intratympanic Dexamethasone in Intractable Unilateral Meniere's Disease.

Authors:  Pradeep Pradhan; Priti Lal; Kanwar Sen
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-06-24

9.  Dexamethasone levels and base-to-apex concentration gradients in the scala tympani perilymph after intracochlear delivery in the guinea pig.

Authors:  Hartmut Hahn; Alec N Salt; Thorsten Biegner; Bernd Kammerer; Ursular Delabar; Jared J Hartsock; Stefan K Plontke
Journal:  Otol Neurotol       Date:  2012-06       Impact factor: 2.311

10.  Toxicology study for magnetic injection of prednisolone into the rat cochlea.

Authors:  M Shimoji; B Ramaswamy; M I Shukoor; P Benhal; A Broda; S Kulkarni; P Malik; B McCaffrey; J-F Lafond; A Nacev; I N Weinberg; B Shapiro; D A Depireux
Journal:  Eur J Pharm Sci       Date:  2018-06-19       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.